Method for producing polypeptide heteromultimer

Patent metadata

Field	Value
Publication number	US-11124576-B2
Application number	US-201415024063-A
Country	US
Kind code	B2
Filing date	Sep 26, 2014
Priority date	Sep 27, 2013
Publication date	Sep 21, 2021
Grant date	Sep 21, 2021

Abstract

It is intended to provide a method for efficiently and stably producing a heteromultimer by incubating, under a reducing condition, homo variants of plural types of polypeptides in which the alteration of amino acids that form the interface between Fc regions and/or the alteration to destabilize the stability of a heavy chain CH3 region has been introduced in the heavy chain CH3 regions so at to achieve the promotion of the dissociation of the Fc regions and/or the control of the association thereof through the use of charge repulsion.

First claim

The invention claimed is:

1. A method for producing a polypeptide heteromultimer, the method comprising:
a) providing a first multimer comprising a plurality of identical first polypeptides, wherein each first polypeptide comprises (i) a human IgG1-type or human IgG4-type CH3 domain, and (ii) a hinge region, and wherein the hinge region of each first polypeptide forms one or more disulfide bonds with the hinge region of another first polypeptide in the first multimer;
b) providing a second multimer comprising a plurality of identical second polypeptides, wherein each second polypeptide comprises (i) a human IgG1-type or human IgG4-type CH3 domain, and (ii) a hinge region, and wherein the hinge region of each second polypeptide forms one or more disulfide bonds with the hinge region of another second polypeptide in the second multimer; and
c) contacting the first multimer with the second multimer under a reducing condition that permits isomerization of hinge region disulfide bonds, thereby producing a polypeptide heteromultimer comprising at least one of the first polypeptides linked via disulfide bond(s) to at least one of the second polypeptides,
wherein the polypeptide heteromultimer is a multispecific antibody or a hetero-Fc fusion protein,
wherein the CH3 domain of each first polypeptide meets any one, two, or three of the following criteria (1) to (3):
(1) amino acid residues at EU numbering positions 356 and 439 in the CH3 domain of each first polypeptide either both have a positive charge or both have a negative charge;
(2) amino acid residues at EU numbering positions 357 and 370 in the CH3 domain of each first polypeptide either both have a positive charge or both have a negative charge;
(3) amino acid residues at EU numbering positions 399 and 409 in the CH3 domain of each first polypeptide either both have a positive charge or both have a negative charge; wherein (x) is true or both of (x) and (y) are true:
(x) each of the first polypeptides and each of the second polypeptides comprises an amino acid residue at EU numbering position 397 that is independently selected from methionine, phenylalanine, and tyrosine;
(y) each of the first polypeptides and each of the second polypeptides comprises an amino acid residue at EU numbering position 392 that is independently selected from aspartic acid, glutamic acid, threonine, valine, and isoleucine; and
wherein the CH3 domains of the first polypeptides or of the second polypeptides or of both the first polypeptides and the second polypeptides have a thermal denaturation temperature (Tm) equal to or lower than 72.5° C. at pH 7.4.

2. The method of claim 1 , wherein the CH3 domain of each second polypeptide meets any one, two, or three of the following criteria (4) to (6):
(4) amino acid residues at EU numbering positions 356 and 439 in the CH3 domain of each second polypeptide either both have a positive charge or both have a negative charge;
(5) amino acid residues at EU numbering positions 357 and 370 in the CH3 domain of each second polypeptide either both have a positive charge or both have a negative charge;
(6) amino acid residues at EU numbering positions 399 and 409 in the CH3 domain of each second polypeptide either both have a positive charge or both have a negative charge;

provided that:
(i) if the CH3 domain of each first polypeptide meets criterion (1) and the CH3 domain of each second polypeptide meets criterion (4), then the amino acid residues at EU numbering positions 356 and 439 of each first polypeptide have a charge opposite to that of the amino acid residues at EU numbering positions 356 and 439 of each second polypeptide;
(ii) if the CH3 domain of each first polypeptide meets criterion (2) and the CH3 domain of each second polypeptide meets criterion (5), then the amino acid residues at EU numbering positions 357 and 370 of each first polypeptide have a charge opposite to that of the amino acid residues at EU numbering positions 357 and 370 of each second polypeptide;
(iii) if the CH3 domain of each first polypeptide meets criterion (3) and the CH3 domain of each second polypeptide meets criterion (6), then the amino acid residues at EU numbering positions 399 and 409 of each first polypeptide have a charge opposite to that of the amino acid residues at EU numbering positions 399 and 409 of each second polypeptide.

3. The method of claim 1 , wherein the first multimer further comprises a third polypeptide, and the second multimer further comprises a fourth polypeptide, wherein the first and second polypeptides are antibody heavy chains, and the third and fourth polypeptides are antibody light chains.

4. The method of claim 1 , wherein the positively charged amino acid residues are selected from lysine, arginine, and histidine; and the negatively charged amino acid residues are selected from glutamic acid and aspartic acid.

5. The method of claim 2 , wherein one of the following (A), (B), or (C) is true:
(A) the CH3 domain of each first polypeptide meets criterion (1) and the CH3 domain of each second polypeptide meets criterion (4), and the amino acid residues at EU numbering positions 356 and 439 of each first polypeptide have a charge opposite to that of the amino acid residues at EU numbering positions 356 and 439 of each second polypeptide;
(B) the CH3 domain of each first polypeptide meets criterion (2) and the CH3 domain of each second polypeptide meets criterion (5), and the amino acid residues at EU numbering positions 357 and 370 of each first polypeptide have a charge opposite to that of the amino acid residues at EU numbering positions 357 and 370 of each second polypeptide;
(C) the CH3 domain of each first polypeptide meets criterion (3) and the CH3 domain of each second polypeptide meets criterion (6), and the amino acid residues at EU numbering positions 399 and 409 of each first polypeptide have a charge opposite to that of the amino acid residues at EU numbering positions 399 and 409 of each second polypeptide.

6. The method of claim 2 , wherein
the CH3 domain of each first polypeptide meets criteria (1) and (3),
the CH3 domain of each second polypeptide meets criteria (4) and (6),
the amino acid residues at EU numbering positions 356 and 439 of each first polypeptide have a charge opposite to that of the amino acid residues at EU numbering positions 356 and 439 of each second polypeptide, and
the amino acid residues at EU numbering positions 399 and 409 of each first polypeptide have a charge opposite to that of the amino acid residues at EU numbering positions 399 and 409 of each second polypeptide.

7. The method of claim 1 , wherein the CH3 domain of each first polypeptide and each second polypeptide comprises an amino acid residue at EU numbering position 392 that is independently selected from aspartic acid, glutamic acid, threonine, valine, and isoleucine.

8. The method of claim 1 , wherein the CH3 domains of the first polypeptides or of the second polypeptides or of both the first polypeptides and the second polypeptides are of IgG1 type.

9. A method for producing a polypeptide heteromultimer, the method comprising:
a) providing a first multimer comprising a plurality of identical first polypeptides, wherein each first polypeptide comprises (i) a mouse IgG-type CH3 domain, and (ii) a hinge region, and wherein the hinge region of each first polypeptide forms one or more disulfide bonds with the hinge region of another first polypeptide in the first multimer;
b) providing a second multimer comprising a plurality of identical second polypeptides, wherein each second polypeptide comprises (i) a mouse IgG-type CH3 domain, and (ii) a hinge region, and wherein the hinge region of each second polypeptide

Assignees

• Chugai Pharmaceutical Co Ltd
• Chungai Seiyaku Kk

Inventors

• Igawa Tomoyuki
• Katada Hitoshi
• Mimoto Futa

Classifications

• C07K16/00 Primary

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C12N15/11

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title

• C07K16/46

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title

• C07K2317/10

  characterized by their source of isolation or production · CPC title

• A61K2039/505

  comprising antibodies · CPC title